Literature DB >> 23329485

Biochemical large-scale identification of MHC class I ligands.

Daniel J Kowalewski1, Stefan Stevanović2.   

Abstract

The large-scale identification of MHC class I presented peptides is indispensable for gaining insight into the fundamental rules of immune recognition as well as it is an invaluable tool in identifying potential targets for the immunotherapy of disease. In this chapter we briefly review the existing strategies for the analysis of MHC ligandomes and provide an in-depth protocol for the immunoaffinity purification of MHC class I presented peptides from primary tissues or cells.

Mesh：

Substances：

Year:  2013        PMID： 23329485     DOI： 10.1007/978-1-62703-218-6_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  41 in total

Review 1.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

2.  HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Authors:  Annika Nelde; Daniel J Kowalewski; Linus Backert; Heiko Schuster; Jan-Ole Werner; Reinhild Klein; Oliver Kohlbacher; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanović; Juliane S Walz
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

3.  Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.

Authors:  Michael Ghosh; Marion Gauger; Ana Marcu; Annika Nelde; Monika Denk; Heiko Schuster; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Mol Cell Proteomics       Date:  2020-01-14       Impact factor: 5.911

4.  The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Authors:  Simon Walz; Juliane S Stickel; Daniel Johannes Kowalewski; Heiko Schuster; Katja Weisel; Linus Backert; Stefan Kahn; Annika Nelde; Tatjana Stroh; Martin Handel; Oliver Kohlbacher; Lothar Kanz; Helmut Rainer Salih; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Blood       Date:  2015-07-02       Impact factor: 22.113

5.  Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.

Authors:  J Patrick Murphy; Youra Kim; Derek R Clements; Prathyusha Konda; Heiko Schuster; Daniel J Kowalewski; Joao A Paulo; Alejandro M Cohen; Stefan Stevanovic; Steven P Gygi; Shashi Gujar
Journal:  J Proteome Res       Date:  2019-05-29       Impact factor: 4.466

6.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Authors:  Daniel J Kowalewski; Heiko Schuster; Linus Backert; Claudia Berlin; Stefan Kahn; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanovic; Juliane Sarah Stickel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

7.  Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Authors:  Martin G Klatt; Daniel J Kowalewski; Heiko Schuster; Moreno Di Marco; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

8.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

9.  Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses.

Authors:  Marijana Rucevic; Georgio Kourjian; Julie Boucau; Renata Blatnik; Wilfredo Garcia Bertran; Matthew J Berberich; Bruce D Walker; Angelika B Riemer; Sylvie Le Gall
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 10.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.